APC-Labeled Human GUCY2C / Guanylyl cyclase C Protein, His Tag (Site-specific conjugation)

分子別名（Synonym）

GUCY2C,GUC2C,STAR,STA receptor,hSTAR,GC-C

表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）

APC-Labeled Human GUCY2C Protein, His Tag (GUC-HA2H4) is produced via conjugation of APC to Human GUCY2C Protein, His Tag with a new generation site-specific technology under optimal conditions with a proprietary technology. Human GUCY2C Protein, His Tag is expressed from human 293 cells (HEK293). It contains AA Ser 24 - Gln 430 (Accession # P25092-1).

Predicted N-terminus: Ser 24

蛋白結(jié)構(gòu)（Molecular Characterization）

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 49.6 kDa.

偶聯(lián)（Conjugate）

APC

Excitation Wavelength: 640 nm

Emission Wavelength: 661 nm

應(yīng)用說(shuō)明（Application）

Please note that this product is NOT compatible to streptavidin detection system.

制劑（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重構(gòu)方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存儲(chǔ)（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

-20°C to -70°C for 12 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

背景介紹

GUCY2C (Guanylyl Cyclase C), also known as heat-stable enterotoxin receptor, is a type I transmembrane protein of the guanylate cyclase (gc) family that signal by producing cGMP. Guanylate cyclase C (GUCY2C) and its hormones guanylin and uroguanylin have recently emerged as one paracrine axis defending intestinal mucosal integrity against mutational, chemical, and inflammatory injury. GUCY2C murine CAR-T cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C. Thus, we have identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the treatment of GUCY2C-expressing metastatic colorectal cancer.